Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level.
Chromosomal abnormalities are used as diagnostic, prognostic and predictive biomarkers to …

Cytogenomic investigations of haematological neoplasms, including chromosome banding
analysis, fluorescence in situ hybridisation (FISH) and microarray analyses have become …

Background Failure of remission-induction therapy is a rare but highly adverse event in
children and adolescents with acute lymphoblastic leukemia (ALL). Methods We identified …

Purpose Minimal residual disease (MRD) and genetic abnormalities are important risk
factors for outcome in acute lymphoblastic leukemia. Current risk algorithms dichotomize …

Recent genomic studies have provided a refined genetic map of acute lymphoblastic
leukemia (ALL) and increased the number of potential prognostic markers. Therefore, we …

Acute lymphoblastic leukaemia (ALL) occurs at all ages but is the most common cancer of
childhood. The current treatment of paediatric ALL is highly successful with up to 90 …

Context.—A complete diagnosis of acute leukemia requires knowledge of clinical
information combined with morphologic evaluation, immunophenotyping and karyotype …

Purpose In the clinical management of children with relapsed acute lymphoblastic leukemia
(ALL), treatment resistance remains a major challenge. Alterations of the TP53 gene are …

Rapid advances in genomics have opened unprecedented possibilities to explore the
mutational landscapes in malignant diseases, such as B-cell acute lymphoblastic leukemia …

Abstract Purpose of Review Rearrangements of the histone lysine [K]-MethylTransferase 2A
gene (KMT2A) gene on chromosome 11q23, formerly known as the mixed-lineage leukemia …